No Data
No Data
Are GLP-1 Drugs Creating Headwinds for Medical Device Makers?
"Strong rivals" are coming one after the other. Eli Lilly and Co (LLY.US) has evaporated over 120 billion US dollars in market cap. Has the "Novartis duo" finally been broken?
Due to at least two competitors making encouraging progress in the treatment of obesity, Eli Lilly and Co.'s position as the leader in the weight-loss drug boom is being threatened, with market cap evaporating more than $120 billion in the past eight days.
FDA Issues Warning on Compounded Versions of Novo Nordisk's Semaglutide
AbbVie Exits Alzheimer's Program on Lack of Differentiation
Eli Lilly Loses $120B in Value Over Viking's GLP-1 Progress
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
No Data